Vical, Pasteur Merieux Serums & Vaccins S.A. deal

The companies expanded their September 1994 research agreement covering the use of VICL's naked DNA vaccine technology. The companies added a sixth vaccine target, herpes zoster, available for option to Pasteur.

VICL also said that it received $4 million when Pasteur Merieux decided in October 1995 to renew its research support to VICL for one year. ...